Empty sella syndrome

Empty sella syndrome
ICD-9	253.8
DiseasesDB	31523
MeSH	D004652

WikiDoc Resources for Empty sella syndrome
Articles
Most recent articles on Empty sella syndrome Most cited articles on Empty sella syndrome Review articles on Empty sella syndrome Articles on Empty sella syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Empty sella syndrome Images of Empty sella syndrome Photos of Empty sella syndrome Podcasts & MP3s on Empty sella syndrome Videos on Empty sella syndrome
Evidence Based Medicine
Cochrane Collaboration on Empty sella syndrome Bandolier on Empty sella syndrome TRIP on Empty sella syndrome
Clinical Trials
Ongoing Trials on Empty sella syndrome at Clinical Trials.gov Trial results on Empty sella syndrome Clinical Trials on Empty sella syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Empty sella syndrome NICE Guidance on Empty sella syndrome NHS PRODIGY Guidance FDA on Empty sella syndrome CDC on Empty sella syndrome
Books
Books on Empty sella syndrome
News
Empty sella syndrome in the news Be alerted to news on Empty sella syndrome News trends on Empty sella syndrome
Commentary
Blogs on Empty sella syndrome
Definitions
Definitions of Empty sella syndrome
Patient Resources / Community
Patient resources on Empty sella syndrome Discussion groups on Empty sella syndrome Patient Handouts on Empty sella syndrome Directions to Hospitals Treating Empty sella syndrome Risk calculators and risk factors for Empty sella syndrome
Healthcare Provider Resources
Symptoms of Empty sella syndrome Causes & Risk Factors for Empty sella syndrome Diagnostic studies for Empty sella syndrome Treatment of Empty sella syndrome
Continuing Medical Education (CME)
CME Programs on Empty sella syndrome
International
Empty sella syndrome en Espanol Empty sella syndrome en Francais
Business
Empty sella syndrome in the Marketplace Patents on Empty sella syndrome
Experimental / Informatics
List of terms related to Empty sella syndrome

'For patient information click here

WikiDoc Resources for Empty sella syndrome
Articles
Most recent articles on Empty sella syndrome Most cited articles on Empty sella syndrome Review articles on Empty sella syndrome Articles on Empty sella syndrome in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Empty sella syndrome Images of Empty sella syndrome Photos of Empty sella syndrome Podcasts & MP3s on Empty sella syndrome Videos on Empty sella syndrome
Evidence Based Medicine
Cochrane Collaboration on Empty sella syndrome Bandolier on Empty sella syndrome TRIP on Empty sella syndrome
Clinical Trials
Ongoing Trials on Empty sella syndrome at Clinical Trials.gov Trial results on Empty sella syndrome Clinical Trials on Empty sella syndrome at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Empty sella syndrome NICE Guidance on Empty sella syndrome NHS PRODIGY Guidance FDA on Empty sella syndrome CDC on Empty sella syndrome
Books
Books on Empty sella syndrome
News
Empty sella syndrome in the news Be alerted to news on Empty sella syndrome News trends on Empty sella syndrome
Commentary
Blogs on Empty sella syndrome
Definitions
Definitions of Empty sella syndrome
Patient Resources / Community
Patient resources on Empty sella syndrome Discussion groups on Empty sella syndrome Patient Handouts on Empty sella syndrome Directions to Hospitals Treating Empty sella syndrome Risk calculators and risk factors for Empty sella syndrome
Healthcare Provider Resources
Symptoms of Empty sella syndrome Causes & Risk Factors for Empty sella syndrome Diagnostic studies for Empty sella syndrome Treatment of Empty sella syndrome
Continuing Medical Education (CME)
CME Programs on Empty sella syndrome
International
Empty sella syndrome en Espanol Empty sella syndrome en Francais
Business
Empty sella syndrome in the Marketplace Patents on Empty sella syndrome
Experimental / Informatics
List of terms related to Empty sella syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Empty sella syndrome (ESS) is defined as herniation of subarachnoid space into the sella turcica (arachnoidocele) in which there is a characteristic radiological finding of "empty sellar space" on magnetic resonance imaging (MRI) and computerized tomography (CT) with a flattened pituitary and elongated stalk. It can be partial if less than 50% of sellar space is filled with cerebro-spinal fluid (CSF), or complete if CSF fills more than 50% of space in the sella and gland thickness is less than 2mm.

Historical Perspective

• The term ‘empty sella’ was first used by Bush in 1951 to describe a peculiar anatomical condition, observed in 40 of 788 human cadavers, particularly females, characterized by a sella turcica with an incomplete diaphragm sellae that forms only a small peripheral rim, with a pituitary gland not absent, but flattened in such a manner as to form a thin layer of tissue at the bottom of the sella turcica.
• In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
• In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].

Classification

• [Disease name] may be classified according to [classification method] into [number] subtypes/groups:

• [group1]
• [group2]
• [group3]

• Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].

There are two types of ESS: primary and secondary.

• Primary ESS happens when a small anatomical defect above the pituitary gland increases pressure in the sella turica and causes the gland to flatten out along the interior walls of the sella turica cavity. Primary ESS is associated with obesity and high blood pressure in women. The disorder sometimes results in a build-up of fluid pressure inside the skull and the pituitary gland may be smaller than usual.

• Secondary ESS is the result of the pituitary gland regressing within the cavity after an injury, surgery, or radiation therapy. Individuals with secondary ESS due to destruction of the pituitary gland have symptoms that reflect the loss of pituitary functions, such as the ceasing of menstrual periods, infertility, fatigue, and intolerance to stress and infection.

Pathophysiology

• The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
• The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
• On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
• On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].

In children, ESS may be associated with early onset of puberty, growth hormone deficiency, pituitary tumors, or pituitary gland dysfunction. MRI scans are useful in evaluating ESS and differentiating it from other disorders that produce an enlarged sella.

Differentiating [disease name] from other Diseases

• [Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:

• [Differential dx1]
• [Differential dx2]
• [Differential dx3]

• Autoimmune factors
• Cavernous sinus thrombosis
• Communicating hydrocephalus
• Congenital absence of the diaphragma sellae
• Diabetes Mellitus
• Familial
• Head trauma
• Increased intracranial pressure
• Radiation therapy complication
• Meningitis
• Pituitary adenoma
• Primary in middle-aged obese women
• Rupture of intrasellar or parasellar cyst
• Sheehan's Syndrome
• Surgery
• Vascular diseases

Differentiating Empty sella syndrome from other diseases:

Empty sella syndrome needs to be differentiated from other diseases causing hypopituitarism.

Diseases	Onset	Manifestations					Diagnosis
		History and Symptoms				Physical examination	Laboratory findings	Gold standard	Imaging	Other investigation findings
		Trumatic delivery	Lactation failure	Menstrual irregularities	Other features
Sheehan's syndrome	Acute	++	++	Oligo/amenorrhea	Symptoms of: Adrenal insufficiency Hypothyroidism	Breast tissue atrophy Decreased axillary and pubic hair growth	Pancytopenia Eosinophilia Hyponatremia Low fasting plasma glucose Decreased levels of anterior pituitary hormones in blood	Clinical diagnosis Most senitive test: Low baseline prolactin levels w/o response to TRH	CT/MRI: Sequential changes of pituitary enlargement followed by: Shrinkage and necrosis leading to decreased sellar volume or empty sella	Pituitary hormone stimulation tests (Metoclopramide and clomiphene citrate stimulation tests)
Lymphocytic hypophysitis	Acute	+/-	+	Oligo/amenorrhea	Associated with autoimmune conditions Generalized headache Retro-orbital or Bitemporal pain Mass lesion effect such as visual field defects	DI Autoimmune thyroiditis	Decreased pituitary hormones(Gonadotropins most common) Hyperprolactinemia(40%) GH excess	Pituitary biopsy: lymphocytic infiltration	CT & MRI: Features of a pituitary mass Diffuse and homogeneous contrast enhancement	Assays for: Anti-TPO Anti-Tg Ab
Pituitary apoplexy	Acute	+/-	++	Oligo/amenorrhea	Severe headache Nausea and vomiting Paralysis of eye muscles (diplopia) Changes in vision	Visual acuity defects CN palsies (nerves III, IV, V , and VI)	Decreased levels of anterior pituitary hormones in blood.	MRI	CT scan without contrast: Hemorrhage on CT presents as a hyperdense lesion MRI: If inconclusive CT	Blood tests may be done to check: PT/INR and aPTT Pituitary hormonal assay
Empty sella syndrome	Chronic	-	+	Oligo/amenorrhea	Erectile dysfunction Headache Low libido	Signs of raised intracranial pressure may be present Nipple discharge	Decreased levels of pituitary hormones in blood.	MRI	Empty sella containing CSF	Pituitary hormone stimulation tests (Metoclopramide and clomiphene citrate stimulation tests)
Simmonds' disease/Pituitary cachexia	Chronic	+/-	+	Oligo/amenorrhea	Cachexia Premature aging	Progressive emaciation Loss of body hair	Decreased levels of anterior pituitary hormones in blood.	MRI	Done to rule out any pituitary cause	Pituitary hormone stimulation tests (Metoclopramide and clomiphene citrate stimulation tests)
Hypothyroidism	Chronic	+/-	-	Oligomenorrhea/menorrhagia	Cold intolerance Constipation	Dry skin Bradycardia Hair loss Myxedema Delayed relaxation phase of deep tendon reflexes	Low T3,T4 Normal/ low TSH Rest of pituitary hormone levels WNL	TSH levels	Done to rule out any pituitary cause	Assays for anti-TPO and anti-Tg Ab FNA biopsy
Hypogonadotropic hypogonadism	Chronic	-	-	Oligo/amenorrhea	Hot flushes Energy and mood changes Decreased libido	Breast tissue atrophy Decreased maturation of vaginal mucosa	Low estrogen, testosterone High FSH/LH	FSH LH	Done to rule out any pituitary cause	Genetic tests  (karyotype) Measurement of total and free testosterone and 17-hydroxyprogesterone concentrations
Hypoprolactinemia	Chronic	-	+	-	Infertility Subfertiliy	Puerperal agalactogenesis	No workup is necessary	Decreased prolactin levels	Done to rule out any pituitary cause	Prolactin assay in 3rd trimester LH, FSH Thyrotropin and free thyroxine
Panhypopituitarism	Chronic	-	+	Oligo/amenorrhea	Polyuria Polydipsia Features of hypothyroidism and hypoadrenalism	Growth failure B/L hemianopsia Papilledema	All pituitary hormones decreased	MRI	Done to rule out any pituitary cause	Left hand and wrist radiograph for bone age
Primary adrenal insufficiency/Addison's disease	Chronic	-	-	-	Hypoglycemia Hypotension	Dehydration Hyperpigmentation loss of pubic and axillary hair	Hyponatremia with/without hyperkalemia Plasma renin activity to aldosterone ratio	Abdominal CT	Abdominal CT	Serum cortisol testing Serum ACTH testing Anti-adrenal Ab testing
Menopause	Chronic	-	+/-	Oligo/amenorrhea	Hot flashes Insomnia Weight gain and bloating Mood changes	Vaginal atrophy Loss of pelvic muscle tone	↑ FSH ↓ Estradiol and inhibin	FSH > LH	Normal	Endometrial biopsy

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

• Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Patient #1: MR images demonstrate an expanded and empty sella

• 
• 
• 

Diagnostic Criteria

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

• There are no specific laboratory findings associated with [disease name].

• A [positive/negative] [test name] is diagnostic of [disease name].
• An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
• Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].

Imaging Findings

• There are no [imaging study] findings associated with [disease name].

• [Imaging study 1] is the imaging modality of choice for [disease name].
• On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
• [Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

• There is no treatment for [disease name]; the mainstay of therapy is supportive care.

• The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
• [Medical therapy 1] acts by [mechanism of action 1].
• Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].

Surgery

• Surgery is the mainstay of therapy for [disease name].
• [Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
• [Surgical procedure] can only be performed for patients with [disease stage] [disease name].

Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

External links

• Template:NINDS